Vaccines

GENEVA, 29 September 2020—Survivors of COVID-19 from 37 countries are among almost 1,000 people who have signed an open letter to pharmaceutical industry leaders calling for a ‘people's vaccine’ and treatments that are available to all – free from patents. The letter comes on the eve of a high-level side event about the pandemic at the UN General Assembly in New York tomorrow (30 September).

The signatories include 242 COVID-19 survivors from South Africa to Finland and New Zealand to Brazil. They also include 190 people in 46 countries who have lost relatives to the virus, and 572 signatories with underlying health conditions that mean they are more likely to develop severe forms of COVID-19 and have a greater risk of dying from it.

The letter says: “Some of us have lost loved ones to this killer disease. Some of us have come close to death ourselves. Some of us are continuing to live in fear that contracting this disease would be fatal for us. We see no justification why your profit or monopolies should mean anyone else should go through this.”

It describes pharmaceutical corporations as “carrying on with business as usual - defending monopolies while refusing to share research and know-how” and calls on industry leaders to “ensure COVID-19 vaccines and treatments reach everyone who needs them by preventing monopolies, ramping up production and sharing knowledge.”

Pharmaceutical monopolies will restrict the production of effective vaccines and treatments to a small number of manufacturers, preventing the mass production that is needed to meet global demand. The letter demands that corporations immediately license vaccine technology and intellectual property rights to the WHO COVID-19 Technology Access Pool (C-TAP).

One of the signatories, Dilafruz Gafurova, 43, from Tajikistan, said: “Me and my husband got sick with this disease. We could only rely on ourselves as hospitals were full … It was really difficult to get the right medicines. I am a mother of four children … I was afraid to leave them alone in this world if something bad could happen with me … The reason I am signing this letter is to help others to get [a] vaccine. Not all the people around the world can get this vaccine, as they simply cannot afford it. They hardly [have enough to meet] their daily needs.”

The letter was organised by the People's Vaccine Alliance, a global coalition of organisations and activists united under a common aim of campaigning for a people’s vaccine for COVID-19 that is based on shared knowledge and is freely available to everyone everywhere.

Tomorrow at the UN General Assembly, Bill Gates and UK Prime Minister Boris Johnson will be among other high-profile figures discussing vaccine access. So far rich nations have failed to exert pressure on pharmaceutical corporations to share technology to maximise the supply of successful vaccines and treatments worldwide.

Heidi Chow from Global Justice Now, a member of the People’s Vaccine Alliance said: “Pharmaceutical companies need to pay attention to the demands of people from around the world who have experienced the fear and devastation of COVID-19. The industry cannot block its ears to these voices but should respond immediately by ending their monopolies and commit to sharing manufacturing know-how. These actions are crucial to expand vaccine supplies so that all countries can affordably access effective vaccines.”

Winnie Byanyima, Executive Director of UNAIDS, said: "With AIDS we saw that when treatments were found the wealthier people in wealthier countries got back to health, while millions of people in developing countries were left to die. We must not repeat the same mistake when a vaccine for COVID-19 is found. The right to health is a human right—it should not depend on the money in your pocket or the colour of your skin to be vaccinated against this deadly virus. A vaccine should be a global public good and free of charge for all."

A COVID-19 VACCINE FOR ALL

The Alliance is also calling on governments to make public funding for research and development of COVID-19 diagnostics, vaccines and treatments conditional on pharmaceutical companies sharing their knowledge and technology free from patents. When an effective vaccine is available, the Alliance demands that doses are fairly distributed with priority given to health workers and other at-risk groups in all countries.

Notes to editors:

Read the full text of the letter

The high-level side events, titled Accelerating the end of the COVID-19 pandemic: taking new solutions to scale and making them equitably accessible, to save lives, protect health systems and restart the global economy, will take place on 30 September at the 75^th session of the UN General Assembly in New York. Among the participants are the UN Secretary General, WHO Director General, leaders of a range of countries including the UK and South Africa and UNAIDS Executive Director Winnie Byanyima.

The open letter has been signed by 941 people. They include 242 COVID-19 survivors from the following 37 countries: Australia, Azerbaijan, Bangladesh, Belgium, Brazil, Burundi, Canada, Denmark, Finland, France, Germany, India, Ireland, Italy, Japan, Kenya, Lebanon, Morocco, Netherlands, New Zealand, Nicaragua, Pakistan, Philippines, Poland, Portugal, Republic of North Macedonia, Russia, Senegal, Slovenia, South Africa, Spain

Sweden, Tajikistan, Uganda, UK, USA and Zambia. Some people fell into more than one category and a list of the signatories is available on request. The letter has been sent to the pharmaceutical companies behind the 11 vaccine candidates that are currently in Phase 3 trials.

People’s Vaccine Alliance is a coalition of organisations and activists united under a common aim of campaigning for a ‘people’s vaccine’ for COVID-19 that is based on shared knowledge and is freely available to everyone everywhere. A global common good. It is coordinated by Oxfam and UNAIDS and its members include Frontline AIDS, Global Justice Now, Nizami Ganjavi International Center, STOPAIDS, Wemos and the Yunus Centre. More than 140 world leaders, former leaders and economists have called on governments to unite behind a people’s vaccine against COVID-19.

Earlier this month, an analysis by Oxfam revealed that a small group of wealthy nations representing just 13 percent of the world’s population have already bought up more than half (51 percent) of the future doses of leading COVID-19 vaccine candidates. 

More than 140 world leaders, experts and elders have made an unprecedented call for guarantees that COVID-19 vaccines, diagnostics, tests and treatments will be provided free of charge to everyone, everywhere

GENEVA, 14 MAY 2020—More than 140 world leaders and experts, including the President of South Africa and Chair of the African Union, Cyril Ramaphosa, the Prime Minister of Pakistan, Imran Khan, the President of the Republic of Senegal, Macky Sall and the President of the Republic of Ghana, Nana Addo Dankwa Akufo-Addo have signed an open letter calling on all governments to unite behind a people’s vaccine against COVID-19. The call was made just days before health ministers meet virtually for the World Health Assembly on 18 May.

The letter, which marks the most ambitious position yet set out by world leaders on a COVID-19 vaccine, demands that all vaccines, treatments and tests be patent-free, mass produced, distributed fairly and made available to all people, in all countries, free of charge.

Other signatories include the former President of Liberia, Ellen Johnson Sirleaf, the former Prime Minister of the United Kingdom, Gordon Brown, the former President of Mexico, Ernesto Zedillo, the former United Nations Development Programme Administrator and former Prime Minister of New Zealand, Helen Clark.

They join notable economists, health advocates and others, from the Chair of the Elders and the former President of Ireland, Mary Robinson, Nobel Laureate, Joseph Stiglitz, to Moussa Faki, Chairperson of the African Union Commission, Dr John Nkengasong, Director of African Centres for Disease Control and Prevention, and Dainius Puras, the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.

“Billions of people today await a vaccine that is our best hope of ending this pandemic,” said Cyril Ramaphosa, President of South Africa. “As the countries of Africa, we are resolute that the COVID-19 vaccine must be patent-free, rapidly made and distributed, and free for all. All the science must be shared between governments. Nobody should be pushed to the back of the vaccine queue because of where they live or what they earn.”

“We must work together to beat this virus. We must pool all the knowledge, experience and resources at our disposal for the good of all humanity,” said Imran Khan, Prime Minister of Pakistan. “No leader can rest easy until every individual in every nation is able to rapidly access a vaccine free of charge.”

The letter, coordinated by UNAIDS and Oxfam, warns that the world cannot afford monopolies and competition to stand in the way of the universal need to save lives.

“This is an unprecedented crisis and it requires an unprecedented response,” said former President of Liberia, Ellen Johnson Sirleaf. “Learning the lessons from the fight against Ebola, governments must remove all the barriers to the development and rapid roll out of vaccines and treatments. No interest is more important than the universal need to save lives"

The leaders recognize that progress is being made and that many countries and international organizations are cooperating multilaterally on research and development, funding and access, including the welcome US$ 8 billion pledged on 4 May at the European Union’s international pledging marathon.

However, as many countries and companies are proceeding with unprecedented speed to develop an effective vaccine, the leaders are calling for concrete commitments to ensure that it is made affordable and available to all in the quickest possible time. These include:

• A mandatory worldwide pooling of patents and sharing of all COVID-19-related knowledge, data and technologies in order to ensure that any nation can produce or buy affordable doses of vaccines, treatments and tests.
• The rapid establishment of an equitable global manufacturing and distribution plan for all vaccines, treatments and tests that is fully funded by rich nations and which guarantees transparent “at true cost prices” and supplies in accordance with need rather than the ability to pay.
  • This would include urgent action to massively increase manufacturing capacity to produce the vaccines in sufficient quantities and train and recruit millions of health workers to distribute them.
• A guarantee that COVID-19 vaccines, treatments and tests are provided free of charge to everyone, everywhere, with priority given to frontline workers, vulnerable people and poor countries with the least capacity to save lives.

“Faced with this crisis, we cannot carry on business as usual. The health of each of us depends on the health of all of us,” said Helen Clark, former Prime Minister of New Zealand. “The COVID-19 vaccine must not belong to anyone and must be free for everyone. Diplomatic platitudes are not enough—we need legal guarantees, and we need them now.”

“Market solutions are not optimal to fight a pandemic,” said Nelson Barbosa, former Finance Minister of Brazil. “A public health care system, including free vaccination and treatment when that becomes available, is essential to deal with the problem, as shown by the Brazilian experience with compulsory licensing of antiretroviral drugs in the case of HIV.”

Uniting behind a people’s vaccine against COVID-19—open letter and full list of signatories

Visit The People's Vaccine website at peoplesvaccine.org

GENEVA, 4 February 2020—The United States National Institutes of Health has announced that its HVTN 702 clinical trial of an HIV vaccine has been stopped. While no safety concerns were found during the trial, the independent data and safety monitoring board found that the vaccine was ineffective in preventing HIV transmission.

The trial, conducted at 14 sites across South Africa, followed more than 5400 HIV-negative 18–35-year-olds over 18 months. The participants received six injections during the six-month period, either the vaccine or a placebo. An analysis undertaken after at least 60% of the participants had been in the study for more than 18 months showed that there were 129 HIV infections among the people who had the vaccine, while 123 people who had the placebo became infected.

“While we are obviously disappointed with the results, important science has been learned that can be carried forward to future trials. I thank the study team for this important vaccine trial,” said Winnie Byanyima, UNAIDS Executive Director.

Other major vaccines are currently being tested at scale—the Mosaico trial, which is testing a vaccine among transgender people and gay men and other men who have sex with men in the Americas and in Europe, and the Imbokodo trial, which is testing a vaccine among women in sub-Saharan Africa. An effective HIV vaccine may well prove to be key for sustaining progress against HIV in the future.

Despite considerable investment in prevention during the trial, there was still an HIV incidence of around 4% per year among the women in the trial. This is simply too high. HIV transmission can be prevented. This requires the right combination of interventions, including HIV testing; antiretroviral therapy for people living with HIV; pre-exposure prophylaxis, condoms and other prevention options; sexual and reproductive health services, including comprehensive sexuality education; keeping girls in school; and the lifting of social, legal and economic barriers for women and girls.

UNAIDS

The Joint United Nations Programme on HIV/AIDS (UNAIDS) leads and inspires the world to achieve its shared vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths. UNAIDS unites the efforts of 11 UN organizations—UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO and the World Bank—and works closely with global and national partners towards ending the AIDS epidemic by 2030 as part of the Sustainable Development Goals. Learn more at unaids.org and connect with us on Facebook, Twitter, Instagram and YouTube.

SEATTLE/GENEVA, 5 March 2019—UNAIDS is greatly encouraged by the news that an HIV-positive man has been functionally cured of HIV. The man was treated by specialists at University College London and Imperial College London for advanced Hodgkin’s lymphoma in 2016 using stem cell transplants from a donor who carried a rare genetic mutation. Researchers report that HIV has been undetectable in the man since he stopped taking antiretroviral medicine 18 months ago.

“To find a cure for HIV is the ultimate dream,” said Michel Sidibé, Executive Director of UNAIDS. “Although this breakthrough is complicated and much more work is needed, it gives us great hope for the future that we could potentially end AIDS with science, through a vaccine or a cure. However, it also shows how far away we are from that point and of the absolute importance of continuing to focus HIV prevention and treatment efforts.”

Stem cell transplants are highly complex, intensive and costly procedures with substantial side-effects and are not a viable way of treating large numbers of people living with HIV. However, the results do offer a greater insight for researchers working on HIV cure strategies and highlight the continuing importance of investing in scientific research and innovation.

The result, reported at the Conference on Retroviruses and Opportunistic Infections in Seattle, United States of America, is one of only two cases of reported functional cures for HIV. The first was the case of the Berlin patient, Timothy Ray Brown, who received similar treatment for cancer in 2007.

There is currently no cure for HIV. UNAIDS is working to ensure that all people living with and affected by HIV have access to life-saving HIV prevention, treatment, care and support services. In 2017, there were 36.9 million people living with HIV and 1.8 million people became newly infected with the virus. In the same year, almost 1 million people died of AIDS-related illnesses and 21.7 million people had access to treatment. 

UNAIDS

The Joint United Nations Programme on HIV/AIDS (UNAIDS) leads and inspires the world to achieve its shared vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths. UNAIDS unites the efforts of 11 UN organizations—UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO and the World Bank—and works closely with global and national partners towards ending the AIDS epidemic by 2030 as part of the Sustainable Development Goals. Learn more at unaids.org and connect with us on Facebook, Twitter, Instagram and YouTube.

The possibilities for new and improved HIV prevention options were showcased at the recent HIV Research for Prevention (HIVR4P) conference, although the participants heard that many new tools are still several years from being ready for implementation.

The importance of pre-exposure prophylaxis (PrEP), including PrEP delivered by a vaginal ring and long-acting PrEP, including injectable PrEP, was featured in many presentations. Vaginal ring PrEP offers better female-controlled prevention options that can protect women without their partner’s knowledge, while injectable PrEP would mean that daily pill-taking and the risk of forgetting to take the pill would be history. Both vaginal ring PrEP and long-acting PrEP are still some way from being available, however, with the vaginal ring currently being reviewed for regulatory approval by the European Medicines Agency and trials for long-acting PrEP not due to deliver results until 2021 or later.

If antibodies and engineered molecules that mimic them can be shown to prevent HIV infection, the way to six-monthly injections for either prevention or treatment could be opened up, along with the possibility of a vaccine that made people develop their own similar antibodies. The participants heard that much progress had been made in discovering and developing such antibodies. The first proof of principle trials showing their effectiveness will report their results in 2020.

“Science has delivered us extraordinary advances in technologies for the diagnosis, treatment and monitoring of HIV infection. There is now real excitement that over the next years it will also lead to effective affordable prevention tools,” said Peter Godfrey-Faussett, Science Adviser, UNAIDS.

The participants heard that there are high levels of sexually transmitted infections (STIs) among the populations at higher risk of HIV and that, as we have known for decades, STIs lead to increased HIV acquisition. The rates of the major treatable bacterial STIs have been rising steadily and are at alarming levels among gay men and other men who have sex with men and young people in eastern and southern Africa, in part due to declining condom usage. The high rates of the major treatable STIs have become particularly evident with the advent of increased screening accompanying the roll-out of PrEP.

Many STIs have no symptoms and can only be diagnosed with modern diagnostic tests—these are simple, but still far too expensive for the countries that need them the most. Along with geography and age group, STIs are among the strongest indicator of risk of HIV. An integrated STI and HIV prevention approach could offer PrEP to people who are HIV-negative but have an STI and live in an area where HIV is prevalent.

New prevention technologies are likely to be relatively expensive and hence will need to be focused on populations at higher risk in order to be affordable and cost-effective. Mathematical modelling shows that these new HIV prevention technologies may have only a limited impact on new HIV infections in eastern and southern Africa. For example, modelling of the impact of the dapivirine ring—a vaginal ring with a slow release of an antiretroviral medicine that protects against HIV infection—shows that only 1.5–2.5% of HIV infections would be averted over the next 18 years in Kenya, Uganda, Zimbabwe and South Africa. With the cost of averting one HIV infection through the use of the dapivirine ring varying from US$ 10 000 to US$ 100 000, many of the participants argued for integrating and combining both HIV treatment and prevention, and the responses to HIV and other diseases, for maximum effect.

The biennial HIVR4P conference was held in Madrid, Spain, from 21 to 25 October.

GENEVA, 17 May 2018—On HIV Vaccine Awareness Day, 18 May, UNAIDS is calling for an increase in research and investment to find an effective vaccine to protect people against HIV and stop new HIV infections. In 2016, around 1.8 million people were newly infected with HIV and although the number of new infections has declined in recent years, the world is still far from achieving the UNAIDS Fast-Track Target of reducing new HIV infections to fewer than 500 000 by 2020.

“New HIV infections are not declining fast enough and stopping infections must become a global priority,” said Michel Sidibé, Executive Director of UNAIDS. “There are 36.7 million people living with HIV today, all in need of costly treatment for life, which will be difficult to sustain over the long term. To truly end AIDS, it is essential to find an effective HIV vaccine and a cure.” 

In mid-2017, more than half (20.9 million) of the 36.7 million people living with HIV had access to antiretroviral medicines to keep them alive and well. Over the next decade, efforts will be scaled up so that all people living with HIV can access the life-saving treatment. Without a cure or a therapeutic vaccine, millions of people will need to be sustained on lifelong treatment.

Promising steps have been made in recent years, with four large-scale trials currently under way and exciting developments in the pipeline. Innovative approaches to immunization are showing great promise in animal models and an ever-increasing array of highly potent broadly neutralizing antibodies have been discovered and can be engineered to persist in the human body so that we may one day be able to prevent HIV infection with a single injection each year.

Safe and effective vaccines have the potential to change the world. Some infectious diseases that were once commonplace, killing millions and leaving countless people with lifelong disabilities, have become rare. Smallpox has been eradicated, only 17 people developed polio in 2017 and in 2016 the Pan American Health Organization declared that measles had been eliminated from the Americas.

An effective, durable, affordable and safe vaccine for HIV would significantly advance efforts to end AIDS. For the past decade, investments have remained steady, at around US$ 900 million per year, which is less than 5% of the total resources needed for the AIDS response. By scaling up investments in HIV vaccine research, diversifying funding and attracting the best scientists from around the world, a vaccine for HIV could become a reality.

UNAIDS

The Joint United Nations Programme on HIV/AIDS (UNAIDS) leads and inspires the world to achieve its shared vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths. UNAIDS unites the efforts of 11 UN organizations—UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO and the World Bank—and works closely with global and national partners towards ending the AIDS epidemic by 2030 as part of the Sustainable Development Goals. Learn more at unaids.org and connect with us on Facebook, Twitter, Instagram and YouTube.

In a dark room, you see a shadow of yourself on a large screen—white lights create spots that arc across the screen and onto your body.

It’s the deadly Shadowpox trying to infect you.

Watching your shadow-self on the screen, you try to sweep the spots off your body. More spots appear and you realize the virus isn’t just attacking you, it’s attacking everyone around you. What do you do now?

This is the type of question people are faced with in Shadowpox, an art installation that is part of the new Immune Nations exhibition. Using interactive projections, Shadowpox gives participants a unique experience of fighting a virus with a vaccine while trying to save the people around them by what public health officials call herd immunity—when enough people are immunized against a disease that other people who are not immunized have some protection against infection, because the spread of contagious disease is contained.

The questions and decisions people face when interacting with Shadowpox are similar to public health scenarios being played out around the world. And it is exactly the kind of thinking a grant by the Research Council of Norway tried to provoke by bringing artists, researchers and policy-makers into a room together to see how they might reframe the current discourse surrounding vaccination.

“We are interested in exploring the role that art and culture could have in informing global health decision-making,” said Steven Hoffman, a law professor at the University of Ottawa and co-lead of the Vaccine Project.

In the summer of 2015, renowned artists and experts gathered at the University of Ottawa, where concepts for the evidence-based art exhibition emerged. Shadowpox was imagined by a group of collaborators led by Alison Humphrey and Caitlin Fisher. The idea started with a new vaccine-preventable disease composed of viral shadows. The concept was part fact and part science fantasy. The mixed-reality installation combines real-world statistical data with live-animated digital effects. “The final work is equally stunning, fun and provoking—everything needed to engage people on the issue of vaccines,” said Natalie Loveless, a co-lead and curator for the exhibition.

The Vaccine Project is a multiyear collaboration that has spanned continents and cultures. “More than 100 people and organizations are collaborating on this exhibition,” said Sean Caulfield, a co-lead of the project. “We have representatives from virtual reality labs and universities to governments and the United Nations.”

The exhibition first premiered at Galleri KiT, Trondheim Academy of Fine Arts, in Norway in March 2017 and travelled to UNAIDS headquarters in Geneva, Switzerland, where it will be opened by the First Lady of Namibia Monica Geingos on 23 May. The works of art will be exhibited at UNAIDS until 30 June 2017. 

GENEVA, 18 May 2017—On the 20th HIV Vaccine Awareness Day, UNAIDS is calling for continued research to find a vaccine for HIV. Although there have been significant discoveries in the field of vaccine research and development, there is still no effective vaccine available against HIV.

New HIV infections have remained stubbornly high for the past 10 years. Every year, 1.9 million adults and more than 150 000 children become infected with the virus. Even if a 90% reduction in new HIV infections is achieved by 2030, there will still be around 200 000 new HIV infections annually, demonstrating how essential a vaccine will be for the long-term control of HIV.

“Despite our major successes in scaling up treatment and ongoing prevention programmes, there are still large numbers of people becoming infected with HIV every year,” said Michel Sidibé, Executive Director of UNAIDS. “The biggest impacts in the eradication or control of infectious diseases in the history of public health have been achieved through vaccination, which is why a vaccine is an objective well worth continuing to invest in.”

Successful antiretroviral therapy requires lifelong adherence, but adherence relies on behaviour change, which can be difficult to maintain. In contrast, an HIV vaccine is a one-time intervention that is extremely cost-effective compared with the cost of lifelong treatment.

A simple-to-use vaccine would be a key tool in reaching the populations most affected by HIV. Models estimate that even a modestly effective vaccine—one that is 50% effective—would have a big impact on the epidemic and may be enough to significantly reduce new HIV infections among key populations.

Industry is helping to take on the challenge of vaccine development. Vaccine candidates are in company pipelines, with some trials starting soon and others during the next few years.

A large vaccine trial, HVTN 702, is in progress in South Africa, with results due in three years. That trial, part of the HIV Vaccine Trials Network, builds on the RV144 trial, which reported in 2009 and was conducted in Thailand, showing a 31% efficacy.

This year, UNAIDS is hosting an art installation on the power of vaccines, reflecting the importance of linking art, advocacy and science. The exhibition, entitled Immune Nations, opens on 23 May and runs until 30 June 2017.

UNAIDS

The Joint United Nations Programme on HIV/AIDS (UNAIDS) leads and inspires the world to achieve its shared vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths. UNAIDS unites the efforts of 11 UN organizations—UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO and the World Bank—and works closely with global and national partners towards ending the AIDS epidemic by 2030 as part of the Sustainable Development Goals. Learn more at unaids.org and connect with us on Facebook, Twitter, Instagram and YouTube.

GENEVA, 18 May 2016—On HIV Vaccine Awareness Day, UNAIDS calls for greater resources and increased collaboration among governments, the scientific community and the private sector to advance research towards finding an effective HIV vaccine.       

“Developing an effective HIV vaccine would be a major scientific and medical breakthrough for humankind,” said UNAIDS Executive Director Michel Sidibé. “Alongside expanding access to existing antiretroviral medicines and combination HIV prevention tools, sustained investment and intensified collaboration to develop an HIV vaccine is needed to bring the world a step closer to ending the AIDS epidemic.”

In 2014, global investment in HIV vaccine research and development increased by 2.8%, to US$ 841 million, up from US$ 818 million in 2013. However, this rebound followed five years during which available resources either flatlined or declined, with a high of US$ 961 million in 2007. The United States of America remains the largest investor in HIV research and development.

Public–private and international partnerships have been formed to accelerate progress towards an effective HIV vaccine. UNAIDS is working together with partners, such as the International AIDS Vaccine Initiative, AVAC and other stakeholders, to advance research. UNAIDS is also an active participant in the annual vaccine funders’ meetings coordinated by the Global HIV Vaccine Enterprise to highlight the importance of continued research, sustained funding and coordinated responses towards HIV vaccine discovery.

Over the past 30 years, four concepts for an HIV vaccine have been tested in six efficacy trials. Of these, the RV144 vaccine trial in Thailand in 2009 was most promising, reducing HIV infection risk by 31%. It is hoped that ongoing research will lead to at least two further large-scale trials of vaccine candidates starting in the near future. At the same time, work continues to develop other potential vaccines, including a combined vaccine for HIV and hepatitis C. The effectiveness of neutralizing antibodies is also being studied.

An HIV vaccine will be necessary for the long-term control of HIV and is the best hope for sustaining the progress made towards ending the AIDS epidemic by 2030.

UNAIDS

The Joint United Nations Programme on HIV/AIDS (UNAIDS) leads and inspires the world to achieve its shared vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths. UNAIDS unites the efforts of 11 UN organizations—UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO and the World Bank—and works closely with global and national partners towards ending the AIDS epidemic by 2030 as part of the Sustainable Development Goals. Learn more at unaids.org and connect with us on Facebook, Twitter, Instagram and YouTube.